Featuring market attractiveness scoring, total addressable market sizing, company benchmarking matrices, interactive Excel dashboards, deeper supply chain intelligence, emerging startup tracking, and granular product-level insights, The Business Research Company’s 2026 market reports are built to deliver research that is both more actionable and more strategically valuable.
Crohn’s Disease Treatment Market Growth Analysis: How Will Revenue Trend Over The Forecast Period?
The market size for Crohn’s disease treatments has shown significant expansion in recent years. It is anticipated to increase from $13.1 billion in 2025 to $13.99 billion in 2026, registering a compound annual growth rate (CAGR) of 6.8%. Historically, this growth has been driven by factors such as the rising prevalence of Crohn’s disease, increased awareness of inflammatory bowel diseases, the growth of hospital pharmacy networks, the availability of conventional anti-inflammatory drugs, and enhancements in diagnostic capabilities.
The crohn’s disease treatment market size is anticipated to demonstrate significant growth over the next few years. It is projected to expand to $18.86 billion in 2030 at a compound annual growth rate (CAGR) of 7.8%. This growth during the forecast period can be attributed to the expanding pipeline of biologics and small molecules, the increasing demand for personalized treatment, greater penetration of online pharmacies, rising healthcare expenditure in emerging markets, and a focus on long-term disease management. Notable trends expected in the forecast period include the rising adoption of biologic therapies, a shift toward early and aggressive treatment approaches, an increasing emphasis on steroid-sparing regimens, the growth of oral small-molecule therapies, and the expansion of online and specialty pharmacy channels.
Get A Free Sample Report With In-Depth Market Insights:
Crohn’s Disease Treatment Market Expansion Drivers: What’s Shaping Future Growth?
The increasing incidence of inflammatory bowel disorders is projected to boost the growth of the Crohn’s disease treatment market in the foreseeable future. Inflammatory bowel disorders encompass a range of chronic conditions marked by inflammation in the gastrointestinal tract. They can lead to inflammation and damage in any section of the digestive system, extending from the mouth to the anus. Crohn’s disease treatment functions by reducing intestinal inflammation, which helps avert symptom flare-ups and sustain remission. For instance, in September 2023, information from the National Center for Biotechnology Information, a US-based government organization, revealed a similar rise in the prevalence of Crohn’s disease and ulcerative colitis, with inflammatory bowel disease projected at 825 cases per 100,000 people in 2023, comprising 410 for Crohn’s disease and 414 for ulcerative colitis and IBD-u. As a result, the rising occurrence of these disorders is spurring the expansion of the Crohn’s disease treatment market.
Crohn’s Disease Treatment Market Segment Analysis And Revenue Potential
The crohn’s disease treatment market covered in this report is segmented –
1) By Drug Type: Antibiotics, Amino Salicylates, Corticosteroids, Immunomodulators, Other Drug Types
2) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies
3) By Application: Neuropathic Pain, Fibromyalgia, Chronic Back Pain, Arthritic Pain, Migraine Post-Operative Pain, Cancer Pain, Other Applications
Subsegments:
1) By Antibiotics: Metronidazole, Ciprofloxacin, Other Antibiotics
2) By Amino Salicylates: Mesalamine, Sulfasalazine, Other Amino Salicylates
3) By Corticosteroids: Prednisone, Budesonide, Other Corticosteroids
4) By Immunomodulators: Azathioprine, Methotrexate, Mercaptopurine
5) By Other Drug Types: Biologics, Small Molecules, Other Treatments
Crohn’s Disease Treatment Market Strategic Trends: What Defines The Next Growth Phase?
Leading companies operating within the Crohn’s disease treatment market are introducing new drugs and obtaining their approval, such as biosimilar ustekinumab, to provide patients with more effective and accessible treatment options, ultimately improving patient outcomes and their quality of life. Biosimilar ustekinumab refers to a biological drug that is highly similar to the original ustekinumab (a monoclonal antibody) utilized for managing autoimmune conditions. For example, in July 2024, Sandoz International GmbH, a Switzerland-based pharmaceutical company, launched Pyzchiva (ustekinumab) across Europe, making it the first ustekinumab biosimilar available in all strengths, including a 130 mg vial specifically for Crohn’s disease. This product is indicated for adults and children over six with plaque psoriasis, psoriatic arthritis, and Crohn’s disease, thereby enhancing Sandoz’s immunology portfolio while aiming to improve access to affordable treatments for chronic inflammatory disease.
Crohn’s Disease Treatment Market Key Players Shaping Industry Direction
Major companies operating in the crohn’s disease treatment market are AbbVie Inc., Janssen Pharmaceuticals, Takeda Pharmaceutical Company Limited, Bristol-Myers Squibb Company, Galapagos NV, Teva Pharmaceutical Industries Ltd., Mylan N.V., Glenmark Pharmaceuticals, Tillotts Pharma AG, Dr. Falk Pharma GmbH, Shire Pharmaceuticals, Salix Pharmaceuticals, Prometheus Laboratories Inc., Pfizer Inc., Novartis AG, Sanofi S.A., Eli Lilly and Company, Boehringer Ingelheim GmbH, Arena Pharmaceuticals Inc., F. Hoffmann-La Roche Ltd.
View The Full Crohn’s Disease Treatment Market Report:
Crohn’s Disease Treatment Market Global Footprint: Which Region Leads The Market?
North America was the largest region in the global Crohn’s disease treatment market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the crohn’s disease treatment market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Reach Out To Our Team:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
